Description

Metformin and Glibenclamide Capsules (I) from Buantang (Shanxi Hengruida Pharmaceutical Co., Ltd.) combine two well-known antidiabetic agents: metformin, a biguanide, and glibenclamide, a sulfonylurea. This capsule formulation is designed for experimental models of type 2 diabetes, focusing on insulin resistance and beta-cell insulin secretion.

Each box contains 12 capsules × 7 blisters, providing sufficient dosage units for controlled research trials or pharmacological assessments.

?? This product is for laboratory and research use only. It is not approved for clinical or human use.

Metformin and Glibenclamide Product Parameters

Metformin and Glibenclamide Mechanism & Research Applications

Metformin primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Glibenclamide stimulates insulin secretion from pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.

Together, these two compounds provide a synergistic antidiabetic effect, making them highly relevant for research in:

• Dual-drug therapy for type 2 diabetes

• Studies on insulin secretion vs. insulin sensitivity

• Glucose tolerance modeling in vivo

• Comparative pharmacokinetics of combination therapies

• Resistance profile evaluations in long-term studies

Metformin and Glibenclamide Observed Effects in Research

• Enhanced glycemic control in diabetic animal models

• Combined effects on fasting and postprandial glucose

• Modulation of insulin secretion kinetics

• Improved glucose tolerance curve profiles

Safety & Handling

• For research or laboratory use only

• Not for human or veterinary administration

• Store in a cool, dry environment

• Use appropriate PPE when handling

• Follow institutional disposal guidelines

Research Use Disclaimer

This product is provided exclusively for laboratory and research use. It is not approved for clinical, diagnostic, or therapeutic applications in humans or animals.